Analysts predict that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will announce ($0.16) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings, with estimates ranging from ($0.17) to ($0.16). Achillion Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year-over-year growth rate of 14.3%. The firm is expected to announce its next earnings report after the market closes on Thursday, August 3rd.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.69) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.68). For the next financial year, analysts forecast that the business will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.67) to ($0.28). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. During the same quarter in the prior year, the company posted ($0.13) earnings per share.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Leerink Swann raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $4.00 to $6.00 in a report on Thursday, May 18th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Finally, Maxim Group decreased their price target on shares of Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $8.75.

A number of large investors have recently bought and sold shares of ACHN. Deschutes Portfolio Strategy LLC increased its stake in Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares in the last quarter. Teza Capital Management LLC acquired a new stake in Achillion Pharmaceuticals during the first quarter valued at approximately $131,000. Dynamic Technology Lab Private Ltd acquired a new stake in Achillion Pharmaceuticals during the first quarter valued at approximately $138,000. Highbridge Capital Management LLC acquired a new stake in Achillion Pharmaceuticals during the first quarter valued at approximately $149,000. Finally, Canada Pension Plan Investment Board increased its stake in Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares in the last quarter. Institutional investors and hedge funds own 71.24% of the company’s stock.

Shares of Achillion Pharmaceuticals (ACHN) traded up 3.89% on Monday, reaching $4.27. 1,124,971 shares of the company traded hands. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.49. The stock’s market cap is $583.81 million. The stock has a 50 day moving average of $4.45 and a 200 day moving average of $4.13.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/24/analysts-anticipate-achillion-pharmaceuticals-inc-nasdaqachn-to-post-0-16-eps.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.